US Bancorp’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-498
| Closed | -$2K | – | 3782 |
|
|
2017
Q4 | $2K | Buy |
498
+496
| +24,800% | +$2.03K | ﹤0.01% | 3511 |
|
|
2017
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 3710 |
|
|
2017
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 3687 |
|
|
2017
Q1 | $0 | Sell |
2
-1
| -33% | -$4 | ﹤0.01% | 3701 |
|
|
2016
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 3715 |
|
|
2016
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 3698 |
|
|
2016
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 3722 |
|
|
2016
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 3745 |
|
|
2015
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 3781 |
|
|
2015
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 3745 |
|
|
2015
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 3701 |
|
|
2015
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 3680 |
|
|
2014
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 3678 |
|
|
2014
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 3619 |
|
|
2014
Q2 | $0 | Sell |
3
-6,366
| -100% | -$112K | ﹤0.01% | 3607 |
|
|
2014
Q1 | $114K | Buy |
6,369
+6,366
| +212,200% | +$105K | ﹤0.01% | 2038 |
|
|
2013
Q4 | $0 | Buy |
+3
| New | +$34 | ﹤0.01% | 3516 |
|
US Bancorp's CASC Position: Q1 2018 in Review
US Bancorp sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 498 shares — an estimated $2K sold.
US Bancorp first reported a position in CASC in Q4 2013 and held it in 17 quarters. The position peaked at $114K in Q1 2014. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- US Bancorp reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- US Bancorp sold 498 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
- US Bancorp first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and held it in 17 quarters.
- US Bancorp's Cascadian Therapeutics, Inc. position peaked at $114K in Q1 2014.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on US Bancorp's 13F filing for Q1 2018, filed 8 May 2018.